Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapy
Haruki Uojima(National Center for Global Health and Medicine), Chika Kusano(Kitasato University), Makoto Chuma(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Satoshi Kobayashi(Kanagawa Cancer Center), Makoto Kako(Shonan Kamakura General Hospital), A Take(Kitasato University), Yoshitaka Arase(Tokai University), Shuhei Nishigori(Yokohama Minami Kyosai Hospital), Tatehiro Kagawa(Tokai University), Nobuhiro Hattori(St. Marianna University School of Medicine), Yoshihiko Sakaguchi(Kitasato University), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Tsunamasa Wanatanbe(St. Marianna University School of Medicine), Takashi Tsuda(Icahn School of Medicine at Mount Sinai), Hisashi Hidaka(Kitasato University), Tomoko Ando(Gifu University), Katsuaki Ogushi(Yokohama City University Medical Center)
Cited by 9
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
|Journal of Biological Chemistry|1990|625
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation.
|Proceedings of the National Academy of Sciences|1981|586